Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Equity Ratio (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Equity Ratio for 15 consecutive years, with 0.7 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 0.86% year-over-year to 0.7, compared with a TTM value of 0.7 through Dec 2025, up 0.86%, and an annual FY2025 reading of 0.7, up 0.86% over the prior year.
  • Equity Ratio was 0.7 for Q4 2025 at Neurocrine Biosciences, roughly flat from 0.7 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.77 in Q3 2024 and bottomed at 0.65 in Q1 2021.
  • Average Equity Ratio over 4 years is 0.7, with a median of 0.7 recorded in 2024.
  • The sharpest move saw Equity Ratio grew 26.98% in 2021, then dropped 8.77% in 2025.
  • Year by year, Equity Ratio stood at 0.67 in 2021, then increased by 2.88% to 0.69 in 2023, then rose by 1.45% to 0.7 in 2024, then increased by 0.86% to 0.7 in 2025.
  • Business Quant data shows Equity Ratio for NBIX at 0.7 in Q4 2025, 0.7 in Q3 2025, and 0.69 in Q2 2025.